September 2024
167 articles-
Sep 30 · 00:01Biotechnology Daily
Malaria drug shows early potential as polycystic ovary syndrome treatment in rodents and people
-
Sep 30 · 00:00Biotechnology Daily
J&J’s DePuy Synthes orthopedics robot cleared for partial knee replacements
-
Sep 29 · 23:58Biotechnology Daily
Siemens Healthineers nets European approval for blood test to predict MS relapse risks
-
Sep 29 · 23:56Biotechnology Daily
Despite high concordance and initial translation, why do animal studies rarely lead to approvals?
-
Sep 29 · 23:54Bio Business News
Syncona merges Freeline and SwanBio to spur new gene-therapy-focused biotech
-
Sep 29 · 23:53Bio Business News
FDA halts trial of BioNTech-MediLink ADC over 'significant risk of illness'
-
Sep 29 · 23:52Bio Business News
Kyverna's CAR-T relapse in lupus dents autoimmune hopes amid biotech gold rush
-
Sep 29 · 23:50Bio Business News
Takeda flunks pivotal epilepsy tests but mulls path to market for Ovid-partnered prospect
-
Sep 26 · 22:25Biotechnology Daily
J&J's phase 2 Sjögren's data support FcRn strategy in the autoimmune disorder
-
Sep 26 · 22:23Biotechnology Daily
FDA joins international push for transparency in AI development
-
Sep 26 · 22:21Biotechnology Daily
Cabaletta's 2-patient CAR-T data hint at autoimmune remission, but investors want more
-
Sep 26 · 22:20Biotechnology Daily
Innovent braves bruising cytokine space, linking fusion protein to tumor responses in small study
-
Sep 26 · 22:19Bio Business News
New EHA data reveal how badly Gilead's $4.9B bet on CD47 imploded
-
Sep 26 · 22:17Bio Business News
enGene drops preclinical cystic fibrosis program to strengthen bladder cancer strategy
-
Sep 26 · 22:16Bio Business News
J.P. Morgan's private financing arm closes inaugural $500M-plus biotech fund
-
Sep 26 · 22:15Bio Business News
Radiopharma biotech Telix drops $200M Nasdaq IPO plans at last minute
-
Sep 25 · 23:14Biotechnology Daily
FDA elevates Medline recall of endotracheal ventilator tubes
-
Sep 25 · 23:12Biotechnology Daily
Ultragenyx wins surrogate endpoint debate, securing green light to seek FDA approval of gene therapy
-
Sep 25 · 23:10Biotechnology Daily
Pfizer's phase 3 gene therapy trial fails to improve function for boys with Duchenne muscular dystrophy
-
Sep 25 · 23:08Biotechnology Daily
Invizius completes first-in-human dialysis trial to quell ‘angry blood’
-
Sep 25 · 23:06Bio Business News
With MDMA debate spreading beyond biotech, Lykos CEO tries to dispel efficacy, safety concerns
-
Sep 25 · 23:04Bio Business News
AbbVie joins TL1A race via $150M upfront deal with China's FutureGen
-
Sep 25 · 23:03Bio Business News
Barinthus lays off 25% of staff, sidelines prostate cancer program to stretch out cash
-
Sep 25 · 23:02Bio Business News
Inflammatory disease biotech launches with $168M and ex-Kite leader at the helm